Skip to main content
. 2010 Jul 26;28(24):3880–3889. doi: 10.1200/JCO.2009.26.9456

Table 3.

Outcome for Adults With De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia by Pretreatment Characteristics (n = 282)

Characteristic No. % % CR P (χ2) % CRD
 P % OS
 P (χ2)
3 Year 5 Year 3 Year 5 Year
Age, years
    Overall 282 95 — 60 50 — 58 50 —
    ≤ 30 96 34 99 .02 63 50 NS 70 64 < .001
    31-59 128 45 98 66 55 60 50
    ≥ 60 58 21 88 53 47 29 21
Sex
    Male 282 57 96 NS 57 60 .1 57 48 NS
    Female 120 43 96 69 45 57 50
Performance status
    0-1 219 78 96 NS 65 55 .04 60 50 NS
    2-3 63 22 97 50 40 50 44
Leukocyte count, ×109/L
    < 5 142 50 96 NS 65 54 < .001 60 49 < .01
    5-29.9 91 32 98 65 54 64 54
    ≥ 30 49 17 94 47 44 42 35
Hemoglobin, g/dL
    < 10 219 78 97 NS 60 62 NS 55 45 NS
    ≥ 10 63 22 94 67 48 59 55
Platelet count, ×109/L
    < 100 214 76 95 NS 60 48 .03 53 43 < .01
    ≥ 100 68 24 98 68 61 69 67
Serum creatinine, mg/dL
    < 1.3 252 89 97 < .01 64 54 .06 60 56 < .01
    ≥ 1.3 30 11 87 51 35 43 25
Serum bilirubin, mg/dL
    < 1.3 254 91 96 NS 64 50 NS 59 50 NS
    ≥ 1.3 27 10 93 45 45 46 41
Serum albumin, g/dL
    < 3 232 83 94 NS 42 39 .01 45 40 .04
    ≥ 3 49 17 97 65 53 60 50
β–2 microglobulin, mg/dL (n = 232)
    < 3 128 55 98 NS 70 55 NS 65 55 .05
    ≥ 3 104 45 95 53 55 52 46
Lactate dehydrogenase, U/L
    < 1,400 161 57 95 NS 60 48 NS 57 50 NS
    ≥ 1,400 121 43 98 60 52 57 48
Systemic risk classification
    Low 81 29 99 NS 64 52 NS 72 65 < .001
    High 200 71 95 63 50 51 43
Karyotype (n = 275)
    Diploid 113 40 96 NS 68 55 NS 60 50 .06
    Hyperdiploid 29 10 97 75 75 65 65
    Hypodiploid 14 5 100 48 39 55 42
    t(1;19) 8 3 100 85 68 62 62
    del 9p 13 5 92 67 45 69 61
    t(4;11), t(11;19), 11q 18 6 94 14 14 20 10
    Other 44 16 93 64 56 59 48
    Insufficient metaphases 36 13 94 49 39 50 42
CD20 expression
    Positive 150 53 94 NS 53 48 .002* 60 52 NS
        Without rituximab 55 93 40 40 45 39
        With rituximab 95 96 67 53 61 49
    Negative 132 47 96 69 52 54 46
Myeloid marker expression (n = 269)
    Positive 125 46 94 NS 64 50 NS 55 45 NS
    Negative 144 54 97 53 50 57 52
Regimen
    Hyper-CVAD 109 39 96 NS 53 46 < .01 55 49 NS
    Modified hyper-CVAD 1 47 17 99 54 44 55 44
    Modified hyper-CVAD 2 126 45 94 78 56 60 50

Abbreviations: CRD, complete remission duration; OS, overall survival; CR, complete remission; NS, not significant; Systemic risk classification: High risk, WBC > 5 × 109/L, > 1 course to CR, Philadelphia chromosome or CNS disease; Low risk, none of these features; Hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; Modified hyper-CVAD 1, anthracycline intensification with or without rituximab; Modified hyper-CVAD 2, no anthracycline intensification with or without rituximab.

*

P value represents comparison with or without rituximab within the CD20-positive group. No differences in rates of CR, CRD, or OS by French-American-British subtype; presence or absence of peripheral blasts; CNS disease at presentation; CNS risk classification; or presence or absence of lymphadenopathy, splenomegaly, and/or hepatomegaly.